S66.AXS66.AXASX
Loading
Star Combo Pharma Limited operates in Australia's household and personal products sector, likely focused on pharmaceutical distribution, OTC medications, or personal care products. The company exhibits characteristics of a small-cap turnaround story with 602% net income growth despite modest 6.9% revenue growth, suggesting significant margin expansion or cost restructuring. Trading at 0.9x sales and 4.0x EV/EBITDA with a 43.9% FCF yield indicates deep value characteristics, though near-zero reported absolute revenue/cash flow figures suggest either data reporting issues or very small scale operations.
The company likely operates as a distributor or retailer of pharmaceutical and personal care products in the Australian market, generating revenue through product margins. The 22.6% gross margin is typical for pharmaceutical distribution, which operates on volume-based thin margins with pricing constrained by regulatory frameworks and competitive dynamics. The dramatic 602% net income growth against 6.9% revenue growth suggests either: (1) successful cost restructuring that turned a loss-making operation profitable, (2) one-time gains or tax benefits, or (3) recovery from a depressed prior-year base. The negative operating margin (-0.9%) contrasted with positive net margin (18.9%) indicates significant non-operating income or tax benefits contributing to profitability.
Gross margin trajectory and ability to sustain 22%+ levels amid competitive pricing pressure
Operating margin inflection from current -0.9% to positive territory through scale or cost discipline
Working capital efficiency given the strong 4.40 current ratio and low 0.10 debt/equity
Contract wins or distribution agreements with pharmaceutical manufacturers or retail chains
Australian healthcare policy changes affecting pharmaceutical pricing or reimbursement structures
Australian Pharmaceutical Benefits Scheme (PBS) pricing reforms that could compress wholesale margins on prescription medications
Consolidation among retail pharmacy chains reducing negotiating leverage for smaller distributors
Direct-to-consumer pharmaceutical e-commerce models disintermediating traditional distribution channels
Generic drug price erosion as patents expire on branded medications in distribution portfolio
Competition from larger pharmaceutical wholesalers (Sigma Healthcare, API) with superior scale economics and national distribution networks
Vertical integration by major pharmacy chains developing in-house distribution capabilities
International entrants leveraging cross-border sourcing to offer lower-cost alternatives
Loss of key supplier relationships or exclusive distribution agreements to larger competitors
Data reporting anomalies showing $0.0B revenue and cash flows raise questions about financial statement quality and transparency
Small market capitalization creates liquidity risk and vulnerability to single-shareholder actions
Sustainability of 18.9% net margin when operating margin is negative suggests reliance on non-recurring items
Limited financial flexibility for growth investments or acquisitions despite low debt levels
low - Pharmaceutical and personal care products exhibit defensive characteristics with inelastic demand regardless of economic conditions. Healthcare spending, particularly on prescription and OTC medications, remains stable through recessions. However, discretionary personal care products may see modest volume pressure during downturns. The Consumer Defensive sector classification reflects this counter-cyclical stability.
Low direct sensitivity given minimal debt (0.10 debt/equity ratio) means financing costs are negligible. However, as a small-cap value stock trading at 0.9x book value, rising rates could pressure valuation multiples as investors rotate away from equities toward fixed income. The company's ability to generate 43.9% FCF yield provides some buffer against rate-driven multiple compression.
Minimal - The pharmaceutical distribution business operates primarily on trade credit cycles with suppliers and customers. The strong 4.40 current ratio indicates robust liquidity and limited reliance on external credit facilities. Tightening credit conditions would have minimal direct impact, though could affect customer payment cycles if retail partners face financing constraints.
value - The stock exhibits classic deep value characteristics with 0.9x P/S, 0.9x P/B, 4.0x EV/EBITDA, and 43.9% FCF yield. The 602% net income growth suggests a turnaround story appealing to special situation investors. The 25.8% one-year return indicates early-stage value recognition, but continued upside requires demonstrating sustainable profitability and operating margin improvement. Small market cap limits institutional participation to micro-cap specialists.
moderate-to-high - Small-cap Australian stocks with limited liquidity typically exhibit elevated volatility. The 0% three-month return versus 8.3% six-month and 25.8% one-year returns suggests episodic price movements rather than steady appreciation. Defensive sector characteristics provide some downside protection, but small float and limited analyst coverage create potential for sharp moves on company-specific news.